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Abstract
Amelioration of rodent type 2 diabetes by hemin has been linked to increased heme oxygenase (HO) activity, however
alternative mechanisms have recently been proposed for its anti-diabetic effect. We sought to determine the anti-diabetic
efficacy of heme arginate (HA), a clinically licensed preparation of heme, and whether its predominant mode of action is via
increased HO activity. Intravenous administration of HA reduced hyperglycemia in diabetic (db/db) mice. Co-administration
of the HO inhibitor stannous (IV) mesoporphyrin IX dichloride (SM) resulted unexpectedly in a further improvement in
glycaemic control despite restoring HO activity to baseline levels. The anti-diabetic effects of HA6SM were associated with
increased adiposity, increased serum adiponectin levels, reduced adipose tissue and islet inflammation and preservation of
islet b-cell function. HO activity independent effects of HA on adipogenesis and b-cell inflammation were further confirmed
in cell culture models using the 3T3-L1 pre-adipocyte and MIN6 b-cell lines, respectively. In conclusion, our work
demonstrates that the heme component of HA ameliorates experimental type 2 diabetes by promoting metabolically
favourable adipogenesis and preserving islet b-cell function, but this is not mediated via increased HO activity.
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Introduction
Heme is a key endogenous regulator of circadian rhythms and
may in addition influence metabolic pathways including gluco-
neogenesis [1] and adipogenesis [2]. Administration of heme, in
the form of repeated intraperitoneal injections of hemin amelio-
rates experimental type 2 diabetes by reducing systemic inflam-
mation, augmenting b-cell insulin secretion, improving peripheral
insulin sensitisation, increasing serum adiponectin levels and by
activating skeletal muscle 59 adenosine monophosphate-activated
protein kinase (AMPK) [3–5].
The anti-diabetic effect of heme was linked to activation of the
heme oxygenase (HO) system [3]. This is comprised of the
inducible (HO-1) and constitutive (HO-2) isoforms and constitutes
the principal pathway of heme degradation, resulting in generation
of iron, carbon monoxide and biliverdin, all of which exhibit
cytoprotective and anti-inflammatory properties [6]. Ndisang and
Jadhav have demonstrated that administration of hemin up-
regulates HO activity in non-obese insulin-resistant Goto-Kakizaki
rats via induction of HO-1 and that the anti-diabetic effect of
heme is abrogated by concurrent administration of an inhibitor of
HO activity, chromium (III) mesoporphyrin IX chloride (CrMP)
[3]. In addition, cobalt (III) protoporphyrin IX chloride (CoPP),
an alternative inducer of HO activity, ameliorates insulin
resistance in obese (ob/ob) mice in a HO activity-dependent
manner [7].
However, administration of heme may have pleiotrophic effects
on metabolism that are independent of HO activity. For example,
binding of heme to the nuclear hormone receptor, Rev-erb-a,
recruits nuclear co-repressor-histone deacetylase 3 complexes
(NCoR–HDAC3) to the promoters of gluconeogenic genes,
thereby inhibiting gluconeogenic gene expression and glucose
output in hepatocytes in vitro [1]. In addition, by acting as a Rev-
erb-a ligand, heme promotes adipogenesis in vitro in an analogous
manner to peroxisome proliferator activator receptor-c (PPAR-c)
agonists [2]. Notably, administration of synthetic Rev-erb agonists
ameliorates glucose intolerance in diet-induced obesity [8].
Heme arginate (HA), in which heme is complexed with L-
arginine (LA) to improve the solubility and stability of the heme
component [9], is licensed for intravenous use in humans in the
treatment of acute porphyria [10], and may therefore be readily be
taken forward in clinical trials in type 2 diabetes. Prior to clinical
use we wished to confirm that HA reduced hyperglycaemia in the
leptin-receptor deficient (db/db) model of type 2 diabetes. In
addition, we wished to confirm the HO activity-dependence of this
effect by concurrently administering stannous (IV) mesoporphyrin
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IX dichloride (SM), an inhibitor of HO activity. Our results
support an anti-diabetic effect for HA, however they challenge the
concept established from previous work that heme is predomi-
nantly acting via induction of HO activity.
Methods
Preparation of Porphyrin-based Chemicals
HA was purchased from Orphan Europe (Paris La De´fense,
France) and diluted to 5 mg/ml in sterile phosphate-buffered
saline (PBS) prior to use in vivo. The HO-1 activity inhibitors,
stannous (IV) mesoporphyrin IX dichloride (SM), and chromium
(III) mesoporphyrin IX chloride (CrMP) and an alternative HO-1
inducer, cobalt (III) protoporphyrin IX chloride (CoPP) were
purchased from Frontier Scientific (Logan, U.S.A.). SM was
diluted to a concentration of 5 mg/ml in 10 mmol/l Tris-NaOH
solution pH 12.0, and adjusted to pH 7.4 using 0.1N hydrochloric
acid prior to in vivo use. For the in vitro experiments SM, CrMP
and CoPP were prepared at a final concentration of 10–20 mM,
pH 7.4 and aliquots were stored at 4uC for 2 weeks prior to use.
All of the porphyrin-based compounds were prepared under
minimal light. All other chemicals were from Sigma Aldrich
(Dorset, U.K.) unless stated otherwise.
In vivo Study Design and Functional Tests
The research was performed under a UK Home Office Project
licence number (60/4002) and approved by the Ethical Review
Committee of the University of Edinburgh. 10 week old male
leptin receptor-deficient db/db mice (Harlan labs, Blackthorn,
U.K.) were allotted into groups matched for baseline weight. A
pilot study comprised three groups of db/db mice (n = 4/group),
which were administered phosphate-buffered saline (PBS), HA
(15 mg/kg) or L-arginine (LA, 16 mg/kg) intravenously twice
weekly for eight weeks. The dose and frequency of HA
administration was based on preliminary studies which demon-
strated that 15 mg/kg significantly induced HO activity with no
evidence of toxicity and that the induction of HO-1 protein began
to diminish by 72 hours following injection (data not shown). The
main study included 4 groups of db/db mice which were treated
with: PBS (n = 4), HA alone (n= 4), SM alone (n= 5), or HA+SM
(n=8). 15 mg/kg HA (or 150 ml PBS) was administered twice
weekly via tail vein injection and 20 mg/kg SM (or 250 ml Tris-
HCl solution) was administered intraperitoneally thrice weekly.
The dose and frequency of administration of SM was identical to
that previously employed to inhibit HO activity in ob/ob mice [7].
Furthermore, in preliminary experiments we confirmed that this
dose was sufficient to abrogate the HA-induced increase in HO
activity (data not shown). As an additional control, 10 week old
lean non-diabetic C57BL/KsJ (lean) mice were treated with
150 ml PBS twice weekly via tail vein.
Body weights were measured weekly. Mice were fasted
fortnightly at 0800 hours and blood glucose concentrations were
measured in tail-nick blood samples taken 4 hours later using a
glucometer (Accu-check Aviva glucometer, Roche, U.S.A.). The
mean daily food intake was determined over a 6-day period during
week 5–6 of the study. Serum insulin, high molecular weight
(HMW) adiponectin, leptin and non-esterified fatty acid (NEFA)
concentrations were determined in the serum of mice after a
4 hour fast using the ultra-sensitive mouse insulin ELISA kit
(Crystal Chem Inc, Downers Grove, U.S.A.), the adiponectin
ELISA kit (Alpco, Salem, U.S.A), the mouse leptin ELISA kit
(Chrystal Chem) and the NEFA–HR2 kit (Wako Chemicals,
Neuss, Germany) respectively, according to the manufacturer’s
guidelines. Homeostatic model assessments (HOMA) for insulin
resistance (HOMA–IR) and b-cell function (HOMA-b) were
calculated using the formulae: HOMA–IR= (Glucose x Insulin)/
22.5 and HOMA-b= (20 x Insulin)/(Glucose –3.5), where the
glucose and insulin values are expressed as mmol/l and mU/l
respectively.
Heme Concentration and Heme Oxygenase Activity
Liver lysates were prepared in phosphate buffer (0.1 M di-
potassium phosphate, 2 mM magnesium chloride, pH 7.4), the
protein concentration was determined using the BCA assay
(Thermo scientific, Wilmington, U.K.) and adjusted to 2 mg/ml.
The heme content in the liver and cell lysates was determined
using the QuantiChrom heme assay kit (BioAssay Systems/
Universal Biologicals Ltd, Cambridge, U.K.).
HO activity was determined by the paired enzyme assay in
which heme is converted into biliverdin by HO and then into
bilirubin by biliverdin reductase in the presence of an NADPH
generating system [11]. Briefly, 1 mg of lysate was added to an
equal volume of master mix (0.2 U glucose-6-phosphatase
dehydrogenase, 4 mM d-glucose-6-phosphate, 100 mM HA,
Table 1. Clinical parameters in the pilot study examining the efficacy of heme arginate (HA) and L-arginine (LA) in the db/db
mouse model of type 2 diabetes.
Parameters PBS (n =4) LA (n =4) HA (n=4)
Fasting glucose (mmol/l)
Week 0 18.062.0 17.962.6 16.860.8
Week 8 31.460.9 28.860.9 16.262.5 *** {{{
Week 8 HbA1C% 8.460.4 7.861.2 4.660.9 *
Body weight (g)
Week 0 44.861.2 43.761.0 44.861.2
Week 8 47.561.7 43.562.1 58.061.2 * {{
Food intake (g/day) 9.160.2 10.160.3 10.260.2
Week 8 Fasting insulin (ng/ ml) 2.460.3 2.760.3 6.561.1 ** {{
Hepatic HO activity (pmol bilirubin mg21 protein hr21) 70.0619.1 90.0619.1 440.0614.8 *** {{{
Data given are means 6 s.e.m. *P,0.05, **P,0.01, ***P,0.001: v PBS. {{P,0.01, {{{P,0.001: v LA. P-values derived from Bonferroni’s multiple comparison post-test
when P,0.05 by one-way analysis of variance. PBS: phosphate buffered saline; HO: heme oxygenase.
doi:10.1371/journal.pone.0078209.t001
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0.4 nM bilirubin reductase A, 2.5 mM NADPH in phosphate
buffer) and incubated in the dark for 1 hour at 37uC in a water
bath. The reaction was stopped by addition of chloroform. The
bilirubin in the chloroform fraction was measured on a
spectrophotometer at A460–A530 (e=40 mM
21 cm21).
Western Blotting for HO-1
Tissues including liver and fat were homogenised in ice-cold
buffer A (50 mM HEPES, pH 7.0, containing 20 mM NaCl,
1 mM DTT, 10 mM sodium pyrophosphate, 10 mM sodium
fluoride, 1 mM sodium orthovanadate and 1x Complete protease
inhibitor cocktail) and centrifuged at 10,000 g for 15 minutes at
4uC to collect the supernatant and quantify protein content using
the BCA assay (Thermo Scientific). Samples of equal protein
content were prepared in 5x laemmli sample buffer and heated for
10 minutes at 95uC. Samples containing 30 mg protein and protein
standard were resolved on 10% Tris-acrylamide gels at 70 V. The
resulting fractionated samples were transferred from the gel onto a
Hybond ECL nitrocellulose membrane (Amersham Biosciences,
Buckinghamshire, U.K.) at 90 V for 1 hour in transfer buffer
(50 mM TRIS, 383.5 mM glycine, 20% (v/v) methanol). The
nitrocellulose membrane containing the transferred proteins was
blocked in 5% (v/v) non-fat milk solution for 1 hour. Membranes
were washed thrice with TBST (50 mM TRIS pH 7.5, 150 mM
NaCl, 0.05% (v/v) Tween-20) between incubations. The mem-
branes were incubated overnight at 4uC with primary antibodies
for HO-1 (Enzo Life Sciences, Exeter, U.K.) and b-actin (Sigma
Aldrich, Dorset, U.K) diluted in 3% milk solution, then incubated
with a species appropriate secondary HRP conjugated antibody
(Dako, Cambridgeshire, U.K.) diluted in 3% milk solution for 1
hour at room temperature before being treated with ECL western
blotting detection reagent (Thermo scientific) and developed.
Immuno-histochemical (IHC) Staining
We employed 5 mm thick sections of paraffin-embedded, methyl
carnoy’s solution-fixed pancreas or fat tissue (serial pancreas
sections were cut at least 75 mm apart). The sections were
deparaffinised, serially rehydrated and blocked with 3% hydrogen
peroxide, Avidin/Biotin blocking kit (Vector laboratories, Peter-
borough, U.K.) and serum-free protein block (Dako, Cambridge-
shire, U.K.) prior to overnight incubation at 4uC with either rat
anti-mouse F4/80 (1:100 dilution; Invitrogen, Paisley, U.K.) or
rabbit anti-mouse iNOS (1:100, BD Transduction laboratory,
Oxford, U.K.). Sections were subsequently incubated with a
species-specific, biotin-labelled secondary antibody (1:300, Vector
laboratories, Peterborough, U.K.) for 2 hours at room tempera-
ture, Vectastain ABC Elite reagent (Vector laboratories, Peterbor-
ough, U.K.) for a further 2 hours and developed with
diaminobenzide (DAB; Dako, Cambridgeshire, U.K.). For co-
staining, the slides were re-blocked and incubated overnight at
4uC with guinea-pig anti-mouse insulin antibody (1:100, Abcam,
Cambridge, U.K.). Sections were subsequently incubated with
biotin-labelled goat anti-guinea pig secondary antibody (1:300,
Abcam, Cambridge, U.K.) for 2 hours at room temperature,
Vectastain ABC Elite reagent (Vector laboratories, Peterborough,
U.K.) for a further 2 hours and stained with HistoGreen
chromogen (Linaris biologische produkte, Germany).
Image-based Quantification
Images of pancreatic islets and adipocytes in epididymal fat pad
were captured at 200x magnification on an Axioskop microscope
(Zeiss, Hertfordshire, U.K.). The mean islet area, number of F4/
80+ and iNOS+ cells/unit islet area, adipocyte number per x200-
power field and adipocyte area were determined using ImageJ
software (National Institutes of Health, Bethesda, MD). A
minimum of 25 islets/mouse was used for islet-based quantifica-
tion. For adipose tissue, a minimum of 10 images/mouse with an
average of 15 adipocytes/image was used for quantifying
adipocyte size and number and percentage area staining F4/
80+. All scoring was performed in a blinded manner by a single
observer.
In vitro Adipogenesis Assay
The murine 3T3 pre-adipocyte cell line (American Type
Culture Collection, ATCC) was plated a density of 125,000/well
in 12-well collagen-coated plates (BD Biosciences, UK) and
cultured in DMEM containing 10% fetal calf serum, 100 U/ml
penicillin, 100 mg/ml streptomycin and 2 mM L-glutamine. A
standard adipogenic induction cocktail comprising 500 mM 3-
isobutyl-1-methylxanthine, 0.25 mM dexamethasone, 1 mg/ml
insulin, and 100 nM rosiglitazone was added and after 48 hours
the medium was replaced with complete DMEM, containing
1 mg/ml insulin for a further 48 hours, then complete DMEM
Figure 1. Administration of SM further augmented HO-1
protein expression but abrogated the increase in HO activity
induced by HA. Representative immuno-blots of HO-1 expression in
A. Epididymal fat and B. Liver. C. Hepatic HO activity in each treatment
group. ***P,0.001, P-values derived from Bonferroni’s multiple
comparison post-test where P,0.05 by one-way analysis of variance.
Data given are means 6 s.e.m.
doi:10.1371/journal.pone.0078209.g001
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Figure 2. HA6SM improved glycaemic control and b-cell function despite a significant increase in body weight in db/db mice. A.
Fasting glucose, B. Body weight, C. HOMA–IR as measure of insulin resistance and D. HOMA-b as measure b-cell function during administration of
PBS (n = 4), HA (n = 4), SM (n= 5) and HA+SM (n = 8) to db/db mice for 8 weeks. {P,0.05: HA v PBS; *P,0.05, **P,0.01, ***P,0.001: HA+SM v PBS,
#P,0.05, ##P,0.01: HA+SM v HA. P-values derived by 2-way ANOVA with Bonferroni’s multiple comparison post-test. Data given are means6 s.e.m.
doi:10.1371/journal.pone.0078209.g002
Table 2. Terminal values of clinical parameters in the main study.
Parameters Lean db/db
PBS PBS HA SM HA+SM
(n=4) (n=4) (n =4) (n =5) (n =8)
HbA1C% 3.060.02 9.060.4
``` 7.860.7 8.460.7 4.860.3 *** {{{
Fasting serum insulin (ng/ml) 0.660.01 2.060.01 3.660.5 * 2.460.1 3.860.5 **
Fasting serum NEFA (mmol/l) 0.660.06 1.060.09 ` 0.660.11 0.760.15 0.560.03 *
HMW Adiponectin (ng/l) 13.061.4 7.361.0 ` 8.360.5 7.660.6 14.161.8 ** {
Leptin (ng/l) 1.460.2 64.063.8 `` 72.7616.2 64.569.1 135.8613.8 ** {{
Body weight gain (g) 2.660.3 -0.261.9 8.660.8 ** 5.961.2 * 14.361.4 *** {
Food intake (g/day) ND 7.960.4 7.060.7 6.760.8 6.160.2
Epididymal fat pad weight (g) ND 1.060.01 1.460.13 * 1.360.03 1.560.1 **
Liver weight (g) ND 3.060.1 4.160.2 3.860.5 4.160.3
Hepatic heme concentration
(mM mg21 protein)
ND 4266 71611 56611 112626 *
Lean (C57BL/KsJ) mice were treated with phosphate-buffered saline (PBS) alone and db/db mice were treated with either PBS, heme arginate (HA), stannous (IV)
mesoporphyrin IX dichloride (SM) or HA+SM.
Data given are means 6 s.e.m. `P,0.05, ``P,0.01, ```P,0.001: Lean PBS v db/db PBS; *P,0.05, **P,0.01, ***P,0.001: v db/db PBS. {P,0.05, {{P,0.01, {{{P,0.001: v
db/db HA. P-values derived from Bonferroni’s multiple comparison post-test where P,0.05 by one-way analysis of variance.
doi:10.1371/journal.pone.0078209.t002
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only for the remaining 6 days. Throughout the differentiation
process, the induction cocktail was supplemented with either PBS,
20 mM HA, 20 mM SM, 20 mM CrMP, 20 mM CoPP, 20 mM
HA+SM, 20 mMHA+CrMP or 20 mMHA+CoPP. For analysis of
gene expression, at days 3, 6 and 10 cells were lysed in 350 ml of
RA1 (Macherey-Nagel, Du¨ren, Germany) containing 3.5 ml of b-
mercaptoethanol and stored at280uC for subsequent RNA
analysis. For quantification of lipid droplets at day 10, the cells
were fixed overnight in 10% formalin before staining with 60%
Oil Red solution for 1 hour. The Oil Red was extracted by
incubating with a 4% IGEPAL CA-630 solution made up in
isopropanol and the absorbance at 550 nm was determined.
Culture and Differentiation of Stromal Vascular Fraction
Stromal vascular fraction (SVF) cells were extracted from
subcutaneous and epididymal adipose tissue from HO-1+/2 mice
and wild-type (WT) littermates. Adipose tissue was placed in
KREB isolation buffer (0.118 M NaCl, 5 mM KCl, 1.2 mM
MgSO4.7H2O, 100 mM NaH2PO4, 100 mM Na2HPO4, 1.2 mM
CaCl2, 0.1% D-Glucose, 1% BSA) containing 2% type I
collagenase (Worthington Biochemical Corporation, NJ, USA )
and digested at 37uC for 20 minutes. The digest was then washed
with SVF proliferation culture media (DMEM/HamsF12 1: 1,
10% New-born calf serum, 100 U/ml penicillin, 100 mg/ml
streptomycin and 2 mM L-glutamine, 33 mM biotin, 17 mM
pantothenic Acid, Invitrogen, Paisley, UK). The upper layer
comprising adipocytes was removed and passed sequentially
through 250 mM, 100 mM and 40 mM nylon mesh filters (BD
Biosciences, Oxford, UK). Single cell suspensions were plated on
collagen type 1 coated 6-well plates (BD Biosciences, UK). After 3
days in cell proliferation growth media, cell debris and red blood
cells were washed from the SVF culture. Once confluent, the cells
were trypsinised and transferred to collagen coated 96-well plates.
SVF cells were differentiated in proliferation media containing
insulin (5 mg/ml), dexamethasone (100 nM), apotransferrin
(10 mg/ml), T3 (200 pM), 3-isobutyl-1-methylxanthine (IBMX,
500 mM) and rosiglitazone (2 mM) with either PBS or HA (20 mM)
for 3 days and then for a further 7 days in the same media, but
without IBMX or rosiglitazone. Several wells were undifferenti-
ated to serve as controls. After 10 days of differentiation, cells were
washed, fixed with 10% formalin overnight, stained with 60% oil
red O solution (Sigma, Dorset, UK) and images captured using an
inserted Zeiss axioscope.
Figure 3. HA+SM promotes adipogenesis and reduces inflammatory gene expression in db/db mice A. Relative expression of Pref-1,
PPARc, FASN genes and B. Mean adipocyte number per 200x magnification, C. Mean adipocyte area in the epididymal fat pads of each treatment
group. D. Relative expression of MCP-1a, CD68, iNOS, TNF-a genes, E. Representative figures (200x) and quantification for F4/80 staining in adipose
tissue. Scale bars represent 25 mM *P,0.05, **P,0.01. P-values derived from Bonferroni’s multiple comparison post-test where P,0.05 by one-way
analysis of variance. The data are means 6 s.e.m from n=4–8/group.
doi:10.1371/journal.pone.0078209.g003
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Figure 4. Concomitant administration of SM accentuates adipogenic potential of HA in vitro. A. HO activity, B. Heme concentrations, C.
Quantification of Oil Red staining and D. Representative light microscopic (x100) image of Oil Red uptake in differentiated adipocytes following 10
days treatment of 3T3 cells with an adipogenic differentiation cocktail alone or with the addition of protoporphyrins. B, C: *P,0.05, **P,0.01,
***P,0.001 v PBS; {P,0.05, {{P,0.01 v HA. E. Time course changes in gene expression of adipogenic genes including PPAR-c, Adipoq, FASN in 3T3-
L1 cells treated with an adipogenic differentiation cocktail alone or with the addition of 20 mM HA, 20 mM SM or HA+SM. {{{P,0.001: HA v PBS;
`P,0.05, ```P,0.001: SM v PBS, ***P,0.001: HA+SM v PBS; #P,0.05, ##P,0.01: HA+SM v HA. P-values derived by 2-way ANOVA with Bonferroni’s
multiple comparison post-test. The data are mean 6 s.e.m from n=4/group. F. Representative (200x) images of Oil Red staining of stromal vascular
fraction cells from epididymal fat pads of HO-1+/+ (left) and HO-1+/2 (right) mice either undifferentiated or following differentiation by an adipogenic
cocktail in the presence of HA.
doi:10.1371/journal.pone.0078209.g004
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Inflammatory Response in MIN-6 b-Cells
Cells from the murine insulinoma MIN6 b-cell line (ATCC)
were plated at 500,000/well in 12-well plates for 48 hr in DMEM
containing 15% FCS, penicillin (100 U/ml), streptomycin
(100 mg/ml) and mercaptoethanol (5 ml/ml). The cells were pre-
treated in fresh medium with either PBS or 20 mM SM for 2 hours
before adding 20 mM HA. 4 hours later a cytokine mix (CM)
containing IL-1b (5 ng/ml), IFN-c (100 ng/ml) and TNF-a
(10 ng/ml) was added to the medium and the cells were incubated
for 20 hours and then lysed in 1 ml of TRIZOL reagent and
stored at280uC for subsequent RNA analysis.
Gene Expression Analysis
Total RNA was extracted from 3T3-L1 cells and from
epididymal fat tissues of db/db mice using a NucleoSpin RNA
II kit (Macherey-Nagel), or from TRIZOL-lysed MIN6 b-cells.
RNA was reverse transcribed to cDNA using the high capacity
cDNA reverse transcription kit (Applied Biosystems, Warrington,
U.K.). Real-time PCR was performed on a Fast Real time
7500 PCR machine (Applied Biosystems) in triplicate using the
following TaqMan inventoried primers (Applied Biosystems): Pref-
1 (Mm00839636_g1), PPAR-c (Mm00839636_g1), FASN
(Mm00839636_g1), MCP-1a (Mm00441242), CD68
(Mm00839636_g1), NOS2 (Mm00440502_m1), TNF-a
(Mm00443258_m1), IL-1b (Mm00839636_g1), Cxcl-1
(Mm00839636_g1), 18S (Mm00839636_g1) and TATA box
binding protein (Mm00839636_g1). The relative expression of
target genes relative to invariant control TATA box binding
protein (TBP) or 18S was determined using the 2-DDCt formula.
Statistical Analysis
All data are expressed as mean 6 s.e.m. Multiple treatment
groups were compared either by one-way analysis of variance or
repeated measures two-way ANOVA tests, with Bonferroni’s
multiple comparison post-tests, with the significance threshold set
at p,0.05. All statistical analysis was performed using GraphPad
Prism version 4.0 (GraphPad Software, San Diego, CA, www.
graphpad.com).
Results
The Heme Component of HA Ameliorates
Hyperglycaemia in db/db Mice
An initial pilot experiment confirmed that administration of HA
reduced fasting glucose levels and glycosylated haemoglobin
concentration (HbA1C%) in db/db mice (Table 1). The improve-
ment in glycaemic control occurred despite an increase in body
weight and was associated with an increase in fasting serum insulin
concentration and hepatic heme oxygenase (HO) activity (Table 1).
As HA is a mixture of hemin and LA, an additional control group
was injected with LA at an identical concentration to that present
in 15 mg/kg of HA. Administration of LA alone failed to replicate
Figure 5. HA+SM increases islet area but reduces islet macrophage infiltration and expression of iNOS protein. A. Representative
images of the islets from each treatment group. b-cells are visualised by staining with anti-insulin antibody (green), with either F4/80+ macrophages
(upper panel) or iNOS positive cells (lower panel) stained in brown. Scale bars represent 50 mM. Quantification of B. islet cross-sectional surface area;
and number of C. F4/80+ macrophages or D. iNOS+ cells per unit islet area in each treatment group. `P,0.05, ```P,0.001 v lean PBS, *P,0.05,
**P,0.01, ***P,0.001 v db/db PBS, {{P,0.01 v db/db HA. P-values derived from Bonferroni’s multiple comparison post-test when P,0.05 by one-
way analysis of variance. The data are mean 6 s.e.m from n.25 islets/mouse.
doi:10.1371/journal.pone.0078209.g005
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the changes in metabolic parameters observed with HA treatment
(Table 1).
Inhibition of HO Activity Accentuates the Reduction in
Blood Glucose and Lipids Observed with HA Therapy
To determine whether the anti-diabetic properties of HA were
mediated via an increase in HO activity as previously suggested
[3–5], db/db mice were treated concurrently with HA and SM, a
competitive inhibitor of HO activity. Co-administration of SM led
to a further increase in HO-1 protein expression in the adipose
tissue and liver (Figure 1 A, B), but completely abrogated the HA-
mediated increase in hepatic HO activity (Figure 1C). Despite
similar levels of HO activity, db/db mice treated with HA+SM
had markedly lower fasting glucose (Figure 2A), HbA1C% and
Figure 6. HA6SM reduces cytokine mix (CM) induced pro-inflammatory response in MIN6 b-cell line. Relative gene expression of A.
iNOS, B. IL-1b, C. MCP-1a, D. Cxcl-1 in MIN6 b-cells pre-treated with either PBS, HA, SM or HA+SM prior to stimulation with cytokine mix. E. HO
activity in MIN6 b-cells. *P,0.05, **P,0.01, ***P,0.001. P-values derived from Bonferroni’s multiple comparison post-test when P,0.05 by one-way
analysis of variance. The data are means 6 s.e.m from n=4 independent experiments/group.
doi:10.1371/journal.pone.0078209.g006
Heme Arginate Ameliorates Murine Type 2 Diabetes
PLOS ONE | www.plosone.org 8 October 2013 | Volume 8 | Issue 10 | e78209
non-esterified fatty acid levels (Table 2) compared with PBS-
treated db/db mice. These favourable metabolic parameters were
observed despite a pronounced increase in body weight in
HA+SM-treated animals (Figure 2B). Serial homeostatic model
assessments of insulin resistance (HOMA–IR) suggested that the
initial reduction in serum glucose in the HA+SM-treated mice was
associated with a transient reduction in insulin resistance
(Figure 2C). Terminal serum insulin levels were higher in
HA+SM-treated mice (Table 2) and serial homeostatic model
assessments of b-cell function (HOMA-b) suggested that in the
later stages of the experiment HA+SM treatment improved b-cell
function compared with PBS-treated db/db mice (Figure 2D).
Inhibition of HO Activity Accentuates the Increase in
Adiposity Observed with HA Therapy, but Results in a
Metabolically Favourable Adipose Tissue Phenotype
Co-administration of SM accentuated the increase in body
weight and epididymal fat pad mass (Table 2) observed with HA
treatment alone. This occurred despite similar food intake across
all treatment groups (Table 2). The increased adiposity was
associated with reduced expression of Pref-1 gene but increased
expression of the PPARc and fatty acid synthase (FASN) genes in
the epididymal fat pad (Figure 3A), suggesting that HA+SM
promoted differentiation of pre-adipocytes into mature adipocytes.
Furthermore, the increased in adipose mass was due to hyperplasia
rather than hypertrophy of adipocytes as supported by the
increased number of adipocytes and reduced mean adipocyte
area in HA+SM treated mice (Figure 3 B, C). In keeping with an
increase in adiposity, serum leptin levels (Table 2) were increased
in db/db mice treated with HA+SM. However, adiponectin levels
(Table 2) were restored to the levels observed in lean mice,
suggesting the adoption of a more favourable metabolic pheno-
type. In addition, HA+SM selectively inhibited adipose inflam-
mation, with a reduction in expression of the MCP-1, CD68 and
iNOS, but not TNF-a genes (Figure 3D). There was, however no
difference between the treatment groups in the mean percentage
area of adipose tissue staining for F4/80 (Figure 3E) or in the
serum cytokine profile assessed using a cytokine bead array
including: TNF-a, interferon-c, MCP-1, IL-6, IL-10 and IL-12
(data not shown).
Concurrent Inhibition of HO Activity Potentiates the
Ability of HA to Promote Adipogenic Differentiation of
pre-adipocytes
The potential of HA6SM treatment to promote adipogenesis
was further assessed in vitro using the clonal murine preadipocyte
3T3-L1 cell line. Administration of HA markedly increased HO
activity in 3T3-L1 cells, and this was completely abrogated by
concurrent administration of SM (Figure 4A), resulting in a
marked accumulation of heme intracellularly (Figure 4B). While
addition of either HA or SM to a standard adipogenic induction
cocktail promoted differentiation of 3T3-L1 cells into adipocytes,
this was more marked when they were administered in combina-
tion (Figure 4 C, D). Adipogenic gene profile assessed by changes
in gene expression of PPARc, adiponectin (Adipoq) and FASN
demonstrated that both HA and SM induced adipogenesis during
differentiation of 3T3-L1 cells which was augmented when both
agents were administered concurrently (Figure 4E). Administration
of SM per se promoted adipocyte differentiation, therefore to
exclude the possibility that this was a specific property of SM; we
employed an alternative inhibitor of HO activity, CrMP, which
replicated the findings, observed with SM (Figure 4C). Further-
more, administration of cobalt protoporphyrin (CoPP) also
promoted adipogenesis (Figure 4C). Finally, to avoid confounding
due to non-specific effects of pharmacological HO inhibitors, we
assessed the efficacy of HA in differentiating pre-adipocytes from
the stromal vascular fraction (SVF) of HO-1 wild-type (WT) and
HO-1+/2 mice, observing that HA had a more potent adipogenic
effect in pre-adipocytes from HO-1+/2 mice (Figure 4F).
Administration of HA and SM in Combination Attenuates
Inflammation and Nitro-oxidative Stress in the Islets of
db/db Mice
The HOMA-b data suggested that concurrent HA+SM therapy
may have ameliorated hyperglycaemia in part by preventing the
decline in b-cell function observed in PBS-treated db/db mice
(Figure 1D). As chronic inflammation [12] and nitro-oxidative
stress [13] both promote b-cell dysfunction in type 2 diabetes, we
performed immunohistochemistry to assess macrophage (F4/80+
cells) infiltration and inducible nitric oxide synthase (iNOS)
expression in the islets from each treatment group (Figure 5A).
The mean cross-sectional islet area was greater in db/db mice
than lean mice and this was further increased following
concomitant HA+SM therapy (Figure 5B); therefore the mean
number of F4/80+ and iNOS+ cells was expressed per unit islet
area. Co-administration of HA+SM accentuated the reduction in
macrophage infiltration that was observed with HA therapy alone
(Figure 5C). Furthermore, the number of iNOS+ islet cells in
HA+SM-treated db/db mice was reduced to a comparable level to
that observed in lean mice (Figure 5D).
HA Down-regulates the Pro-inflammatory Response to
Cytokines in a b-Cell Line Independently of HO Activity
The anti-inflammatory potential of HA in b-cells was further
assessed in an in vitro model employing stimulation of the b-cell
(MIN6) line with a pro-inflammatory cytokine mix (CM).
Administration of HA resulted in a significant reduction in the
expression of the iNOS, IL-1b, MCP-1a and Cxcl-1 genes in
MIN6 cells in response to stimulation with CM (Figure 6A–D).
Pre-treatment with SM abrogated the HA-mediated increase in
HO activity in MIN6 cells (Figure 6E), but failed to reverse the
anti-inflammatory effects of HA (Figure 6A–D).
Figure 7. Graph of the correlation between hepatic heme
concentration and terminal level of glycosylated haemoglobin
(HbA1c).
doi:10.1371/journal.pone.0078209.g007
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The Severity of Hyperglycaemia was Inversely Correlated
to Hepatic Heme Concentration
Concurrent administration of HA+SM resulted in a marked
accumulation of heme in the liver of db/db mice compared with
their PBS-treated counterparts (Table 2). Furthermore, the hepatic
heme concentration was inversely correlated to HbA1c levels
(Figure 7), suggesting that higher levels of heme were associated
with improved glycaemic control.
Discussion
In the current study, we determined that the heme component
of HA ameliorates hyperglycaemia in the db/db mouse model of
type 2 diabetes; however, in contrast to previous research [3], we
observed that concomitant administration of an inhibitor of HO
activity, SM, does not abrogate the anti-diabetic effect of HA but
rather accentuates it, indicating that the primary mode of action of
heme is not via an increase in HO activity.
Although heme has previously been shown to ameliorate
experimental type 2 diabetes, it was administered in the form of
intraperitoneal injections of hemin [3–5], an approach that is
impractical for use in humans. As a prelude to a clinical trial of
heme therapy for type 2 diabetes, we administered HA to db/db
mice to determine the efficacy of a more soluble and translation-
ally relevant preparation which is currently licensed in Europe for
the treatment of acute porphyria. Encouragingly, serial intrave-
nous injections of HA resulted in a modest reduction of blood
glucose levels in db/db mice.
We hypothesised that HA was acting via an increase in HO
activity, as has been demonstrated previously with hemin [3];
however, despite restoring HO activity to baseline levels,
concurrent administration of SM augmented the favourable
metabolic effects of HA therapy. We acknowledge that the
assessment of HO activity is based solely on hepatic levels and
given the key phenotypic changes observed in adipose tissue, we
attempted to also confirm this in epididymal fat pads, however this
was unsuccessful for technical reasons. However, SM did
successfully inhibit HO activity in the 3T3-L1 pre-adipocyte cell
line, therefore we have no reason to suspect that a similar effect
was not observed in adipose tissue in vivo. The reason for the
discrepancies between the effects we observed with concurrent
administration of heme and inhibition of HO activity and those of
previous studies are unclear. We employed an identical regime of
SM administration to that used previously in abrogating an
increase in HO activity in ob/ob mice [7]. While it is possible that
SM may have specific off-target effects, administration of CrMP,
an alternative inhibitor of HO activity that was employed in
previous studies to suppress the hemin-mediated increase in HO
activity [3] had an identical effect to SM on adipogenesis in vitro.
That the adipogenic potential of HA was greater in vascular
stromal fraction cells from HO-1+/2 mice compared with WT
mice, supports the concept that the metabolic effects of HA are
accentuated rather than diminished by a reduction in HO activity
and that therefore induction of HO activity is not the primary
mechanism for the anti-diabetic effect of heme. This is in keeping
with recent studies in which mice with myeloid-specific HO-1
haploinsufficiency were protected from diet-induced insulin
resistance [14].
A critical question is how HA and SM interact to produce such
a profound reduction in blood glucose levels in db/db mice. One
possibility is that concurrent administration of SM potentiates the
rise in intracellular heme concentration achieved by HA alone by
inhibiting activity of HO, the predominant heme degrading
enzyme. This is supported by the close inverse correlation between
the hepatic heme concentration and glycosylated haemoglobin
levels. That increased heme may ameliorate hyperglycaemia in
db/db mice is of particular interest given recent data indicating
that heme is an endogenous ligand for the nuclear hormone
receptor, Rev-erb-a. Heme binding to Rev-erb-a reduces gluco-
neogenesis in hepatocytes in vitro, and Rev-erb agonists ameliorate
glucose intolerance in mice with diet-induced obesity [8].
It is evident that co-administration of HA and SM had
pleotropic effects on several organs that are integral to glucose
homeostasis. Administration of SM potentiated the anti-diabetic
effect of HA despite promoting further weight gain and increasing
adiposity. The expansion of adipose tissue was driven by
hyperplasia rather than hypertrophy and mediated at least in
part by differentiation of pre-adipocytes into adipocytes as
reflected by the reduction in expression of the pre-adipocyte gene,
Pref-1 and the increase in PPAR-c, a gene highly expressed in
differentiated adipocytes [15,16]. In addition, the marked reduc-
tion in fasting non-esterified fatty acid (NEFA) levels attained with
HA+SM therapy suggests that concomitant therapy may also
inhibit lipolysis. Despite the increase in adiposity, the combination
of HA+SM promoted a metabolically favourable adipose tissue
phenotype. While leptin levels increased markedly with HA+SM
treatment, as would be expected with the increase in adiposity,
serum adiponectin concentration was restored to the level
observed in lean mice. This may promote insulin sensitivity via
stimulating AMPK activity in muscles [17]. Indeed, the serial
HOMA–IR data point to an early reduction in insulin resistance
and this may be an integral component of the anti-diabetic effect
of combinatorial treatment. In keeping with previous studies (3–5),
HA+SM therapy may have selective anti-inflammatory properties
in adipose tissue. HA+SM reduced gene expression of the
chemotactant MCP-1, which may account for the reduced
infiltration of activated macrophages (CD68 and iNOS genes).
These results must be treated with caution, however, given the fact
that there was no difference between treatment groups in TNF-a
gene expression or F4/80 staining.
The adipogenic potential of HA and SM is supported by the
in vitro data where co-administration of SM potentiated the ability
of HA to promote differentiation of the pre-adipocyte 3T3-L1 cell
line into adipocytes. This was associated with an increase in
intracellular heme concentration, which is pertinent as heme has
previously been shown to promote adipogenesis in vitro, as is also
observed with synthetic Rev-erb-a ligands [18]. Interestingly,
cobalt protoporphyrin also promoted adipogenesis, suggesting that
this may be a generic feature of porphyrins, rather than specific to
heme per se.
Progressive b-cell dysfunction is a key factor in the pathogenesis
of type 2 diabetes in humans and this is replicated in db/db mice
as evidenced by the progressive fall in the HOMA-b in the PBS-
treated group during the in vivo study. Concomitant treatment with
HA and SM partially reversed the fall in the HOMA-b in the later
stages of the study. Islet inflammation, and in particular
macrophage accumulation, plays a key role in b-cell dysfunction
in type 2 diabetes [12,19], therefore it is pertinent that
administration of HA and SM not only dampened the inflamma-
tory response to cytokines in the MIN6 b-cell line, but also
reduced macrophage accumulation in the islets of db/db mice.
The increased iNOS staining observed in the islets of PBS-treated
db/db mice may also contribute to b-cell dysfunction as iNOS-
derived nitric oxide inhibits insulin secretion from b-cells in vitro
[20] and, furthermore, iNOS inhibitors ameliorate b-cell dysfunc-
tion in rodent models of type 2 diabetes [13]. Hence, the marked
reduction in islet iNOS staining observed with concomitant HA
and SM treatment may be a key mechanism for the preservation
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of b-cell function observed. Furthermore, the Rev-erb-a agonistic
properties of heme may also be important, as it has recently been
demonstrated that Rev-erb-a promotes insulin exocytosis and b-
cell proliferation in MIN6 b-cells in vitro [21].
In conclusion, the present study confirms the anti-diabetic
efficacy of HA in experimental type 2 diabetes via pleiotropic
effects on adipose tissue and by reducing islet inflammation. These
effects were potentiated by inhibition of HO activity; hence the
present study challenges an established paradigm that porphyrin-
based compounds ameliorate type 2 diabetes via induction of HO
activity. Future studies are required to establish the anti-diabetic
efficacy of HA in the diet-induced model of type 2 diabetes and to
incisively delineate the molecular mechanisms responsible for
pleotropic effects of heme on metabolic processes in vivo.
Acknowledgments
We thank Dr Melissa Cudmore for providing the HO+/2 mice and wild-
type littermates, Dr. Forbes Howie for his assistance with measuring
HbA1C% and Bob Morris and Susan Harvey for the preparation of the
histological sections.
Author Contributions
Conceived and designed the experiments: BC AC NM DK JH. Performed
the experiments: AKC JR CC GB BRC. Analyzed the data: AKC BRC.
Wrote the paper: AKC BRC. Contributed to and approved the final
version of the manuscript: BC AC JR CC GB JH NM DK. Contributed to
the discussion and reviewed/edited the manuscript: JR GB JH NMM DK.
Will act as guarantors and are responsible for the contents of the article:
AKC BRC.
References
1. Yin L, Wu N, Curtin JC, Qatanani M, Szwergold NR, et al. (2007) Rev-
erbalpha, a heme sensor that coordinates metabolic and circadian pathways.
Science 318: 1786–1789.
2. Kumar N, Solt LA, Wang Y, Rogers PM, Bhattacharyya G, et al. (2010)
Regulation of adipogenesis by natural and synthetic REV–ERB ligands.
Endocrinology 151: 3015–3025.
3. Ndisang JF, Jadhav A (2009) Up-regulating the hemeoxygenase system enhances
insulin sensitivity and improves glucose metabolism in insulin-resistant diabetes
in Goto-Kakizaki rats. Endocrinology 150: 2627–2636.
4. Ndisang JF, Lane N, Jadhav A (2009) The heme oxygenase system abates
hyperglycemia in Zucker diabetic fatty rats by potentiating insulin-sensitizing
pathways. Endocrinology 150: 2098–2108.
5. Ndisang JF, Lane N, Jadhav A (2009) Upregulation of the heme oxygenase
system ameliorates postprandial and fasting hyperglycemia in type 2 diabetes.
Am J Physiol Endocrinol Metab 296: E1029–1041.
6. Grochot-Przeczek A, Dulak J, Jozkowicz A (2012) Haem oxygenase-1: non-
canonical roles in physiology and pathology. Clin Sci (Lond) 122: 93–103.
7. Li M, Hyun Kim D, Tsenovoy PL, Peterson SJ, Rezzani R, et al. (2008)
Treatment of Obese Diabetic Mice with an Heme Oxygenase Inducer Reduces
Visceral and Subcutaneous Adiposity, Increases Adiponectin Levels and
Improves Insulin Sensitivity and Glucose Tolerance. Diabetes.
8. Solt LA, Wang Y, Banerjee S, Hughes T, Kojetin DJ, et al. (2012) Regulation of
circadian behaviour and metabolism by synthetic REV–ERB agonists. Nature
485: 62–68.
9. Tenhunen R, Tokola O, Linde´n IB (1987) Haem arginate: a new stable haem
compound. Journal of Pharmacy and Pharmacology 39: 780–786.
10. Tokola O, Tenhunen R, Volin L, Mustajoki P (1986) Pharmacokinetics of
intravenously administered haem arginate. British journal of clinical pharma-
cology 22: 331–335.
11. McNally SJ, Ross JA, James Garden O, Wigmore SJ (2004) Optimization of the
paired enzyme assay for heme oxygenase activity. Anal Biochem 332: 398–400.
12. Donath MY, Boni-Schnetzler M, Ellingsgaard H, Ehses JA (2009) Islet
inflammation impairs the pancreatic beta-cell in type 2 diabetes. Physiology
(Bethesda) 24: 325–331.
13. Kato Y, Miura Y, Yamamoto N, Ozaki N, Oiso Y (2003) Suppressive effects of a
selective inducible nitric oxide synthase (iNOS) inhibitor on pancreatic beta-cell
dysfunction. Diabetologia 46: 1228–1233.
14. Huang JY, Chiang MT, Yet SF, Chau LY (2012) Myeloid heme oxygenase-1
haploinsufficiency reduces high fat diet-induced insulin resistance by affecting
adipose macrophage infiltration in mice. PLoS One 7: e38626.
15. Wang Y, Kim KA, Kim JH, Sul HS (2006) Pref-1, a Preadipocyte Secreted
Factor That Inhibits Adipogenesis. The Journal of Nutrition 136: 2953–2956.
16. Lazar MA (1999) PPARy in Adipocyte Differentiation. Journal of Animal
Science 77: 16–22.
17. Towler MC, Hardie DG (2007) AMP-activated protein kinase in metabolic
control and insulin signaling. Circ Res 100: 328–341.
18. Kumar N, Solt LA, Wang Y, Rogers PM, Bhattacharyya G, et al. (2010)
Regulation of Adipogenesis by Natural and Synthetic REV–ERB Ligands.
Endocrinology 151: 3015–3025.
19. Ehses JA, Perren A, Eppler E, Ribaux P, Pospisilik JA, et al. (2007) Increased
number of islet-associated macrophages in type 2 diabetes. Diabetes 56: 2356–
2370.
20. Thomas HE, Darwiche R, Corbett JA, Kay TW (2002) Interleukin-1 plus
gamma-interferon-induced pancreatic beta-cell dysfunction is mediated by beta-
cell nitric oxide production. Diabetes 51: 311–316.
21. Vieira E, MarroquA˜ L, Batista TM, Caballero-Garrido E, Carneiro EM, et al.
(2012) The Clock Gene Rev-erba Regulates Pancreatic Beta-Cell Function:
Modulation by Leptin and High-Fat Diet. Endocrinology 153: 10.
Heme Arginate Ameliorates Murine Type 2 Diabetes
PLOS ONE | www.plosone.org 11 October 2013 | Volume 8 | Issue 10 | e78209
